EWTX
Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company in Boulder, Colorado that makes swallowed pills designed to treat serious muscle diseases. Its drugs tune myosin, the protein that drives muscle contraction, to protect fragile fibers in muscular dystrophies and to ease the stiff, thickened heart muscle of hypertrophic cardiomyopathy. Founded in 2017 by four scientists and drug developers, the company went public on Nasdaq in 2021.
CUSIP: 28036F105HealthcareUS1 holder
Total Value
$60.91M
Total Shares
3.34M
Net Share Change
-2.82M
Activity
1 selling
Investor
Value
Shares
Weight
Change
